Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Delays Between CRC Presentation, Treatment Not Associated With Poor Survival in Young Adults
August 3rd 2023Adults younger than 50 years with colorectal cancer (CRC) who experience postpresentation delays in treatment did not appear to have worse outcomes, according to a study in Ontario, Canada.
Read More
Laura Wingate: Education Makes Patients More Confident in Biosimilar Switches
August 3rd 2023There is a right way and a wrong way to inform a patient about a switch from the reference product to a biosimilar, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Read More
Dr Haley Naik: Improved Medical Education Can Help Reduce Diagnostic Delays of HS
July 30th 2023Some populations face longer diagnostic delays for hidradenitis suppurativa (HS), but medical education can help improve knowledge of common dermatologic diseases and reduce delays in diagnosis, said Haley Naik, MD, FAAD, associate professor of dermatology, University of California, San Francisco, School of Medicine.
Read More
Laura Wingate on the Unique Situation of 7 Adalimumab Biosimilars Coming to Market at Once
July 24th 2023Despite having 8 adalimumab biosimilars on the market now, patients may only see 1 or 2 available through their insurance, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Read More
Patients With Hidradenitis Suppurativa Face Many Barriers When Accessing Care, Says Dr Haley Naik
July 23rd 2023Some of the many barriers patients with hidradenitis suppurativa (HS) face include accessing knowledgeable providers, insurance coverage of treatment, and the way the health care system is set up, said Haley Naik, MD, FAAD, associate professor of dermatology, University of California, San Francisco, School of Medicine.
Read More
Dr Emma Guttman-Yassky: Strong Real-World Results of Biologics, JAK Inhibitors in AD
July 16th 2023Some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have been better in practice compared with clinical trials, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai.
Read More
Patient Education Can Prevent Nocebo Effect With Adalimumab Biosimilars, Explains Laura Wingate
July 15th 2023As Humira biosimilars enter the market, patient education about biosimilars is crucial to prevent the nocebo effect when patients switch from the reference product, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Read More
CMS Proposes $9 Billion Lump-Sum Repayment to 340B Hospitals
July 10th 2023After the Supreme Court ruled reimbursement cuts to 340B hospitals were done unlawfully, CMS is proposing to repay hospitals and providers in the program with a lump sum that has repercussions for other hospitals because of the agency’s need to be budget neutral.
Read More
Oncology Practices Made Shifts Toward Biosimilar Use, but Payer Challenges Remain
July 5th 2023Two abstracts presented at the 2023 American Society of Clinical Oncology annual meeting evaluated biosimilar adoption across oncology practices and highlighted the role payers play in preventing or promoting adoption.
Read More
Dr Robert Dellavalle Discusses the Importance of Diversity in Clinical Trials
July 2nd 2023Unless all populations are represented adequately in trials, it will be hard to know if a drug works the same in all populations as it does in one specific one, explained Robert Dellavalle, MD, PhD, MSPH, of University of Colorado School of Medicine and Rocky Mountain Regional VA Medical Center.
Read More
Dr Byron Lam Highlights Treatments in the Pipeline for Inherited Retinal Disease
June 26th 2023Gene therapy is only one exciting area of treatments in the pipeline to potentially treat inherited retinal disease, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.
Read More
SmithRx to Offer Adalimumab Biosimilar Yusimry at 90% Discount to Humira
June 14th 2023The pharmacy benefit manager SmithRx has announced that through a partnership with the Mark Cuban Cost Plus Drug Company, it will offer Yusimry, an adalimumab biosimilar, for less than 90% of the cost of the reference product, Humira.
Read More
Dr Byron Lam Reviews Current Treatments and Therapies in the Pipeline for Inherited Retinal Disease
June 11th 2023The most exciting treatment for inherited retinal disease was approved in 2017, but there are many novel treatments in phase 2 or phase 3 trials at this point, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.
Read More
Mandatory Switch Policies Drive Biosimilar Uptake, Reduce Costs
June 2nd 2023Abstracts presented at EULAR 2023 highlighted the impact that a mandatory switching policy had on biosimilar uptake in British Columbia, Canada, and the lack of uptake when no such policy was in place in the United States.
Read More